

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

Evaluating the feasibility of study methods for a future trial-based economic evaluation of a multistage shared decision-making program for type 2 diabetes mellitus: protocol for a cluster-randomized controlled pilot study

A. Tichler<sup>1\*</sup>, D.F.L. Hertroijs<sup>1</sup>, G.A.P.G. van Mastrigt<sup>1</sup>, M.C.G.J. Brouwers<sup>2,3</sup>, D. Ruwaard<sup>1</sup>, A.M.J. Elissen<sup>1</sup>

<sup>1</sup>Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, the Netherlands

<sup>2</sup>Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, the Netherlands

<sup>3</sup>Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands

\*Corresponding author:  
E-mail: [a.tichler@maastrichtuniversity.nl](mailto:a.tichler@maastrichtuniversity.nl) (AT)

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 28 **Abstract**

### 29 **Introduction**

30 We developed a multistage shared decision-making program for type 2 diabetes that aims to  
31 support person-centered type 2 diabetes management in primary care. The program consists of an online  
32 patient decision aid, a preparatory consult for patients, and interprofessional training for healthcare  
33 professionals. The short- and long-term effectiveness of the multistage shared decision-making program  
34 needs to be researched in a trial-based economic evaluation. To evaluate the feasibility of study methods  
35 for future economic evaluation, we will conduct a pilot study that focuses on sample recruitment and  
36 retention, study management, and feasibility of outcome and cost measurements.

37

### 38 **Methods and analysis**

39 The multistage shared decision-making program will be pilot-tested in a cluster-randomized  
40 controlled trial in four primary care practices (located in the region of Gorinchem, the Netherlands)  
41 using a mixed-methods approach. The intervention practices will adopt the program, whereas the control  
42 practices provide usual care. Data collection will include recruitment, retention, and consent rates,  
43 patients' sociodemographic and clinical characteristics, and the assessment of primary and secondary  
44 outcomes of the future trial-based economic evaluation. We will also collect data on the usage behavior  
45 of patients when completing questionnaires of the primary and secondary outcomes (i.e. time needed to  
46 complete questionnaires). Semi-structured interviews with patients will be conducted to obtain insights  
47 into the understandability and usability of measurement tools. Moreover, focus groups with healthcare  
48 professionals from participating practices will be organized to complement the quantitative data on  
49 sample representativeness and to assess the study management challenges of participating practices.

50

## 51 **Discussion**

52           The pilot will address uncertainties around the feasibility of a future trial-based economic  
53 evaluation, focusing on sample recruitment and retention, study management, and the feasibility of  
54 outcome and cost measurements. The results will guide the improvement of study procedures for the  
55 economic evaluation of our multistage shared decision-making program for type 2 diabetes.

56

## 57 Introduction

58 Type 2 diabetes mellitus (T2DM) is associated with significant levels of morbidity and  
59 mortality, reduced quality of life, and increased healthcare costs [1]. National and international clinical  
60 guidelines for T2DM emphasize the need for person-centered care, including shared decision-making  
61 (SDM), to decide on the best treatment course for an individual patient [2-4]. SDM is complex in T2DM  
62 care due to the availability of many pharmacological and lifestyle treatment options. Patients and  
63 healthcare professionals (HCPs) face difficult trade-offs in aligning treatment attributes (e.g. efficacy,  
64 side effects) with patients' clinical factors and preferences. SDM support is needed to reap the full  
65 benefits of person-centered T2DM care. We developed a multistage SDM program for T2DM that  
66 combines (1) an online patient decision aid (PDA) with (2) a preparatory consult for patients, and (3)  
67 interprofessional training in the PDA and SDM for HCPs [5]. The program was co-created with patients  
68 with T2DM, healthcare professionals involved in T2DM care, and patient organizations.

69 Evidence shows that PDAs, in general, can reduce patients' decisional conflict, make them  
70 better informed, more involved and satisfied with their treatment choices, and have a positive effect on  
71 the communication between patients and HCPs [6]. There is some evidence suggesting that PDAs,  
72 through their effective support of SDM, can lead to improvements in treatment adherence and  
73 persistence, thereby resulting in better health outcomes and cost reduction [6]. However, the available  
74 evidence for these effects remains limited [6]. Our multistage SDM program for T2DM is a complex  
75 intervention as defined by the Medical Research Council (MRC) [7]. It consists of multiple, interacting  
76 components, targets a diverse group of end-users, and influences a range of short- and long-term  
77 outcome measures. A trial-based economic evaluation with the multistage SDM program needs to be  
78 conducted to estimate short- and long-term effectiveness. It will strengthen the limited evidence about  
79 the impact of person-centered care and SDM on mid and long-term outcomes such as treatment  
80 adherence, health outcomes, and costs.

81 Previous randomized controlled trials researching the effects of SDM support through PDAs for  
82 T2DM experienced several challenges related to study procedures (e.g. recruitment), resources (e.g.  
83 time necessary to complete questionnaires), and study management (e.g. personnel and data

84 management for participating practices) [8-12]. These challenges include, for example, difficulties in  
85 recruiting patients, understandability of questionnaires, timely recruitment, and inadvertent recruitment  
86 bias. Recognizing the challenges faced in previous research, small-scale piloting is crucial to address  
87 uncertainties around the feasibility of study methods and to improve the study procedures of an  
88 economic evaluation [12, 13]. This article outlines the protocol for a cluster-randomized controlled pilot  
89 study aimed at evaluating the feasibility of a future trial-based economic evaluation of a multistage SDM  
90 program, including a PDA for T2DM in the Netherlands, compared to usual care [5]. The pilot study  
91 specifically focuses on sample recruitment and retention, study management, and feasibility of outcome  
92 and cost measurements. A mixed-methods approach will be used to identify and address potential  
93 challenges for future trial-based economic evaluation.

94

## 95 **Research questions**

96 The pilot aims to address uncertainties around the feasibility of study methods. This includes the  
97 need for strategies to deal with recruitment and retention challenges to ensure a study sample that  
98 represents the diverse group of patients with T2DM for the intended economic evaluation [14].  
99 Moreover, acknowledging the high workload and time constraints experienced by HCPs, we aim to gain  
100 insights into how to minimize additional burdens on participating practices [15, 16]. Finally, considering  
101 the complexity of the measurement process and the understandability of the measurement tools, the  
102 outcomes and costs will be measured in the pilot study to refine study procedures for the intended  
103 economic evaluation. Therefore, the research questions of this pilot study are:

- 104 1. What strategies can be employed to effectively recruit and retain a demographically and  
105 clinically diverse sample of patients with T2DM?
- 106 2. How can we support primary care practices in effectively managing the challenges associated  
107 with study participation?
- 108 3. How can we feasibly measure relevant SDM outcomes, treatment adherence, health outcomes,  
109 and costs from a societal perspective for T2DM using valid and reliable measurement  
110 instruments?

## 111 **Methods and analysis**

112 This protocol follows a combination of the Consolidated Standards of Reporting Trials  
113 (CONSORT) extension to pilot trials [17] and the Standard Protocol Items: Recommendations for  
114 Interventional Trials (SPIRIT) checklist for reporting protocol studies [18, 19], as described by Thabane  
115 et al. [20] (S1-S2 File). For conducting and reporting the future economic evaluation, the Dutch  
116 guidelines for economic evaluation [21] and the Consolidated Health Economic Evaluation Reporting  
117 Standards 2022 (CHEERS 2022) Statement [22] will be followed, respectively. The pilot study starts  
118 February 2024 and will last 15 months: 9 months for implementation (i.e. patient recruitment and data  
119 collection) of the multistage SDM program, and 6 months for data analysis and reporting.

120

## 121 **Setting**

122 The majority of patients with T2DM in the Netherlands (90% in 2022) are treated in a primary care  
123 setting organized by care groups [23]. Care groups are collaborations between healthcare professionals  
124 (general practitioners and affiliated personnel) and are responsible for organizing, coordinating, and  
125 providing care for patients with T2DM in their region [24]. A team comprising a general practitioner  
126 and practice/diabetes nurse provides treatment following the national guidelines for T2DM of the NHG  
127 [25]. Since most Dutch patients with T2DM are treated in primary care, the multistage SDM program  
128 was developed based on the NHG guideline for T2DM and will be pilot-tested in a general practice  
129 setting. Therefore, we collaborate with the primary care group ‘Huisarts & Zorg’, a group of 75 general  
130 practices located in the region of Gorinchem (a municipality in South Holland) to recruit practices and  
131 patients. Four primary care practices from the care group ‘Huisarts & Zorg’ will be included in this pilot  
132 study.

133

## 134 **Study design**

135 The multistage SDM program will be piloted in a cluster-randomized controlled trial using a  
136 mixed-methods approach to answer questions related to sample recruitment and retention, study

137 management, and feasibility of outcome and cost measurements. Randomization will be conducted by  
138 cluster (i.e. primary care practices) to avoid possible contamination between the intervention and control  
139 group [26]. Two primary care practices will be randomly assigned to the intervention group and two to  
140 the control group. Simple randomization will be used to assign each primary care practice to a group  
141 with an equal probability (1:1 allocation) using a computerized random number generator [27]. Both  
142 patients with T2DM and HCPs are not blinded to the group assigned to them. Patients and HCPs from  
143 the intervention practices will have access to the multistage SDM program. They will receive an account  
144 to gain access to the PatientPlus platform, where the PDA is available. Patients and HCPs from the  
145 control practices will provide and receive usual care according to the national guidelines for T2DM of  
146 the Dutch College of General Practitioners (NHG) [25]. They will not have access to the multistage  
147 program. Data will be collected from patients and healthcare professionals in both the intervention and  
148 control practices.

149

## 150 **Participants**

151 To be able to recruit a diverse population of patients with T2DM, we aim to include general  
152 practices from the care group ‘Huisarts & Zorg’ that differ in terms of the sociodemographic background  
153 of their patient panels. HCPs from the participating practices will be asked to recruit patients who: 1)  
154 are eighteen years or older; 2) need to decide on T2DM treatment based on the NHG guideline  
155 (medication and/or lifestyle); and 3) speak Dutch at a necessary level to complete questionnaires and  
156 ensure involvement in SDM. We will only exclude patients who have severe cognitive impairments that  
157 hamper SDM. Patients will be enrolled in the study after receiving face-to-face and written information  
158 about the research from their HCP and after giving written informed consent.

159

## 160 **Intervention**

161 The multistage SDM program combines an online PDA with a preparatory consultation for  
162 patients as well as an interprofessional training in the PDA and SDM for HCPs (Fig 1). The program

163 was co-created with a multidisciplinary steering group representing all relevant stakeholders in Dutch  
164 diabetes care. The development of the PDA for T2DM is described in detail elsewhere [5].

165

166 **Fig 1. Overview of the multistage shared decision-making program for type 2 diabetes mellitus.**

167 SDM: shared decision-making; PDA: patient decision aid; T2DM: Type 2 Diabetes Mellitus.

168

169 The PDA is available in the online catalog of PatientPlus ([https://www.keuzehulp.info/front-](https://www.keuzehulp.info/front-page/keuzehulpen/diabetes-type-2)  
170 [page/keuzehulpen/diabetes-type-2](https://www.keuzehulp.info/front-page/keuzehulpen/diabetes-type-2), Dutch only), the largest supplier of PDAs in the Netherlands. In line  
171 with the International Patient Decision Aids Standards (IPDAS) guidance, the PDA comprises five  
172 sections: 1) information about T2DM and the available treatment options; 2) a comparison of treatment  
173 options based on, for example, the risk of cardiovascular disease and effect on daily life; 3) questions to  
174 assess patients' knowledge; 4) value-clarification exercise; and 5) summary of the patient's journey [28,  
175 29].

176 To prepare and empower patients for SDM, our multistage program comprises a one-to-one  
177 preparatory consultation with a trained facilitator. Each practice can decide whether a practice nurse,  
178 medical assistant or other HCP will serve as a trained facilitator. The consultation will last 20-30 minutes  
179 and is intended to help patients effectively use the PDA and provide them with the knowledge and  
180 confidence needed to fully participate in SDM. The preparatory consultation takes place before the  
181 clinical encounter where the treatment decision is made by a patient and HCP (i.e. a GP or specialized  
182 nurse who can prescribe medication).

183 All participating HCPs (including the trained facilitators) from included intervention practices  
184 receive a 2-hour interactive interprofessional training in SDM and the PDA, including communication  
185 techniques and general instructions to increase SDM knowledge. HCPs will receive accreditation for  
186 their participation in the training. The training is offered by PatientPlus. One intervision meeting  
187 between the trained facilitators from all participating practices will be held to stimulate interprofessional  
188 training.

189



## 190 **Sample size calculation**

191 The pilot study is a preparation for a large trial-based economic evaluation and therefore setting  
192 the sample size for the pilot study in order to minimize the total sample size of the pilot study and main  
193 trial together is the most suitable method of sample size calculation [30]. The sample size calculation  
194 for the pilot study is based on a 90% powered main trial and an estimated medium (between 0.3 and 0.7)  
195 effect size in the decisional conflict score (primary outcome of the intended economic evaluation) [31].  
196 Using the stepped rules of thumb, the sample size for the pilot study would be 30 patients with T2DM  
197 [30]. Due to possible loss to follow-up and drop-out, the sample size will be increased by a third. So,  
198 the sample size for this pilot study will be set at 40 patients with T2DM, with 20 patients assigned to  
199 each arm.

200

## 201 **Outcome measures**

202 The pilot study will focus on three aspects: 1) sample recruitment and retention; 2) study  
203 management; and 3) feasibility of outcome and cost measurements. Each aspect has its own relevant  
204 outcome measures and measurement instruments.

205

## 206 **Research question 1. Sample recruitment and retention**

207 To assess the extent to which a representative sample of T2DM patients is included and retained,  
208 quantitative data will be collected on: (1) recruitment, retention and consent rates; (2) time required to  
209 recruit the target sample size; and (3) sociodemographic and clinical characteristics. To interpret the  
210 quantitative data and learn how to improve sample representativeness for the intended trial-based  
211 economic evaluation, additional qualitative data will be collected through one-hour focus groups with  
212 HCPs from the participating practices.

213

## 214 **Research question 2. Study management**

215 The focus groups with HCPs from participating practices will also be used to assess practices'  
216 study management challenges. An interview guide, consisting of a set of semi-structured questions  
217 related to study management (e.g. did the practice have the time to perform the tasks they committed to  
218 doing? Did they experience any capacity issues?) will be used to guide the focus group.

219

## 220 **Research question 3. Feasibility of outcome and cost measurements**

221 We will assess the feasibility of primary and secondary outcome measurements of the intended  
222 trial-based economic evaluation. The primary and secondary outcomes will solely be measured to assess  
223 its measurement feasibility and not to determine the (cost-)effectiveness and cost-utility of the  
224 multistage SDM program. The primary outcomes will focus on short-term SDM outcomes. Primary  
225 outcomes include patient decisional conflict (using the 16-item Decisional Conflict Scale, DCS [32]),  
226 level of SDM as perceived by patients (based on the 3-item CollaboRATE survey [33, 34] and SDM-  
227 Q-9 questionnaire [35]), level of SDM as perceived by HCPs (using the SDM-Q-Doc questionnaire  
228 [35]), and patient knowledge (with 9 tailor-made questions assessing patient's understanding of the  
229 glucose-lowering treatments). The DCS, CollaboRATE, SDM-Q-9, and SDM-Q-Doc questionnaires  
230 will be used for this pilot study due to their validity and wide applicability in assessing SDM in  
231 healthcare. The long-term cost-effectiveness and cost-utility of our multistage SDM program will serve  
232 as secondary outcomes in the intended trial-based economic evaluation. Assessing societal costs and  
233 health-related quality of life is essential for conducting a cost-utility analysis since it allows us to  
234 compare the multistage program with usual care by estimating how much it costs to reach improvements  
235 in individuals' quality of life [36]. Moreover, in the future trial-based economic evaluation, we will also  
236 conduct a cost-effectiveness analysis to estimate how much it costs to reach improvements in relevant  
237 health outcomes (i.e. glycemic control). Therefore, secondary outcomes include glycemic control  
238 (HbA1c obtained via the HCP), societal costs (measured with an adapted version of the iMTA  
239 Productivity Costs Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ) [37,  
240 38]), health-related quality of life (measured with the Dutch EuroQol (EQ) 5D-5L questionnaire

241 assessing quality of life [39]), and medication adherence (measured with the Medication Adherence  
242 Report Scale [40] and prescription data obtained via the pharmacist).

243 Table 1 provides an overview of the primary and secondary outcomes of the future trial-based  
244 economic evaluation, including their measurement tools. Semi-structured interviews with patients will  
245 be held to gain insight into the understandability and accessibility of the measurement tools. Interviews  
246 will be conducted either in person or online via Microsoft Teams, depending on the preference of the  
247 patient. Moreover, we will collect data on the usage behavior of patients when completing the  
248 questionnaires (i.e. time needed to complete questionnaires) and the amount of missing data. The focus  
249 groups with HCPs from participating practices will also be used to evaluate the understandability of the  
250 SDM-Q-Doc questionnaire.

251

252 **Table 1. Outcomes of the intended large-scale trial-based economic evaluation, including their**  
253 **measurement tools.**

Outcome	Measurement tool	Components
<b>Patients</b>		
Decisional Conflict	Decisional Conflict Scale (DCS) [32]	Patients will be asked to reflect on the treatment decision they made with their HCP and respond to 16 statements in the DCS using a five-point Likert scale (from completely agree to completely disagree).
Level of SDM	CollaboRATE survey [33, 34]	3 statements that assess patients' perception of being informed and engaged in decision-making steps on a scale of zero (no effort was made) to nine (every effort was made)
	SDM-Q-9 questionnaire [35]	The questionnaire contains nine statements each describing a different step of the SDM process. All items are scored on a six-point Likert scale from zero

(completely disagree) to five (completely agree). The questionnaire also includes two open-ended questions on what health problem was the subject of the consultation and which decision was made.

Patient knowledge	9 tailor-made multiple-choice questions	Assessing patients' understanding of the (risks and benefits of) glucose-lowering treatments.
Medication adherence	Medication Adherence Report Scale (MARS) [40]  Prescription data	Assessing intentional and unintentional non-adherence (self-reported). Patients are asked to rate the frequency of events (i.e. forgetting a dose, changing a dose) on a five-point Likert Scale (ranging from never to always).  Patients' pharmacy records for all T2DM medication will be collected.
Glycemic control	Primary care data	Glycemic control is assessed by obtaining HbA1c data from the primary care practice.
Costs (resource use)	An adapted version of the iMCQ and iPCQ questionnaire [37, 38]	The adapted version of the iMTA Productivity Costs Questionnaire (iPCQ) and the iMTA Medical Consumption Questionnaire (iMCQ) aims to measure relevant (non-)healthcare use as well as costs important to patients and families.
Health-related quality of life	Dutch EuroQol (EQ) 5D-5L (quality of life) [39]	The EQ 5D-5L assesses quality of life and includes the EQ-5D dimension and the EQ visual analog scale (VAS). EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain, and anxiety. Each dimension of the EQ-5D is scored on a five-point Likert score (from no problems to extreme problems). The EQ

VAS is used to assess the patient’s self-reported health on a visual analog scale.

### Healthcare professionals

Level of SDM	SDM-Q-Doc questionnaire [35]	SDM-Q-9 questionnaire adapted to the HCP viewpoint to assess the extent of SDM during a consultation from the HCP perspective.
--------------	------------------------------	--

254 HCP: healthcare professional; SDM: shared decision-making.

## 255 Data collection and timeline

256 Patients from the intervention practices are requested to complete the questionnaires via the  
257 online PatientPlus platform and patients from the control practices will complete questionnaires via  
258 Qualtrics [41]. They will receive automatic notifications (via mail) prompting them to complete the  
259 follow-up questionnaires at 3 and 9 months follow-up. Additionally, automated reminders will be sent  
260 if the patient has not yet completed the questionnaire. HCPs from the control and intervention practices  
261 will complete the questionnaire via Qualtrics [41]. The schedule of study enrolment and assessment can  
262 be found in Table 2. Baseline measurements will capture sociodemographic and clinical patient  
263 characteristics, patient knowledge, medication adherence, costs, and health-related quality of life. In  
264 both study arms, patients complete the DCS, CollaboRATE survey, and SDM-Q-9 questionnaire directly  
265 following the clinical encounter where a treatment decision is made. At the same time, HCPs complete  
266 the SDM-Q-Doc questionnaire. Follow-ups at 3 months and 9 months will facilitate the measurement  
267 of medication adherence, costs, and health-related quality of life. Semi-structured interviews with  
268 patients will be held within 1 month after study participation and the focus groups with HCPs from  
269 participating practices will be held at the end of the 9 months of implementation. Upon completion of  
270 data collection at 9-month follow-up, we will gather information on the glycemetic control (at baseline,  
271 and 3- and 9-month follow-up) of participating patients by obtaining their HbA1c values through their  
272 primary care practice.

273

274 **Table 2. Schedule of study enrolment and assessment.**

		Enrolment			
Time point		t0	t1	t2	t3
Enrolment	Eligibility	x			
	Informed consent	x			
Assessment	Sociodemographic and clinical characteristics	x			
	Decisional Conflict		x	x	x
	Patient-rated level of SDM		x	x	x
	HCP-level of SDM		x	x	x
	Patient knowledge	x			
	Medication adherence	x		x	x
	Glycemic control	x		x	x
	Costs (resource use)	x		x	x
	Health-related quality of life	x		x	x
	Semi-structured interviews with patients		x		
	Focus group with HCPs				x

275 t0 = baseline measurement; t1 = directly following the clinical encounter where a treatment decision is  
 276 made; t2 = 3-month follow-up; t3 = 9-month follow-up. SDM: shared decision-making, HCP: healthcare  
 277 professional.

278

## 279 **Data analysis**

280 Descriptive analysis, i.e. counts and percentages for non-continuous data and mean scores and  
 281 standard deviations for continuous data, will be reported for all variables. This includes  
 282 sociodemographic and clinical characteristics, outcomes of the future economic evaluation, and  
 283 estimates related to feasibility (e.g. recruitment rates and time to complete questionnaires). Moreover,  
 284 we will analyze the missing data by identifying the amount of missing data and complementing this  
 285 information with the results of the qualitative analysis. Descriptive analysis will be performed in Rstudio

286 [42]. Due to the nature of the pilot study, no statistical tests on the primary and secondary outcomes will  
287 be conducted.

288 Interviews and focus groups will be audio-recorded and transcribed ad verbatim, and analyzed  
289 in ATLAS.ti using thematic analysis with an inductive approach following three steps [43, 44]. First,  
290 the transcripts will be read and re-read in a process called ‘familiarization’. Second, phrases, sentences,  
291 and paragraphs with meaningful topics will be isolated and labeled by a code for each interview  
292 transcript (independently by two researchers). Third, themes are developed by clustering codes with  
293 similar meanings or interrelations, to understand, interpret, and report the main insights flowing from  
294 the data. Analysis of the interviews and focus groups will be used to improve the questionnaires (e.g.  
295 formulation of questions and possible adaptation to the cost questionnaire), recruitment strategies, and  
296 study procedures.

297 The data management process (i.e. data collection, data processing, data quality, and data  
298 analysis) and possible improvements thereof will be discussed with the research team in three 2-hour  
299 meetings throughout the study period.

300

## 301 **Ethical considerations and declarations**

302 The Medical Ethics Review Committee of the academic hospital of Maastricht (azM) and  
303 Maastricht University confirmed that the Medical Research Involving Human Subjects Act does not  
304 apply to the pilot study and that official approval is not required (METC2023-0114). Patients will be  
305 enrolled in the study after receiving face-to-face and written information about the research and after  
306 giving written informed consent. Participants’ data will be used and retained by the researchers of  
307 Maastricht University in compliance with the EU General Data Protection Regulation. Some of the data  
308 will be collected via PatientPlus. PatientPlus has an information security management system that is  
309 ISO27001 and NEN7510 certified. Researchers will be provided with an account for PatientPlus to  
310 access the research data of patients. PatientPlus has only access to the anonymized data. The collected  
311 data will be stored on the secure server of Maastricht University. All participants in this study will be  
312 given an ID number to ensure the confidentiality of the patients and HCPs. Data in reports and

313 publications of this pilot study will not be traceable to the research participants. Research participants  
314 have the right to withdraw from the research and withdraw their consent to the use of personal data at  
315 any time during the study.

316

## 317 **Discussion**

318 This protocol outlines the approach for pilot testing our multistage SDM program in primary  
319 care. Our primary objective is to address uncertainties around the feasibility of study methods, focusing  
320 on aspects such as sample recruitment and retention, study management, and the feasibility of outcome  
321 and cost measurements. Given that T2DM affects a large and diverse group of patients, it is important  
322 to ensure that the study participants accurately represent this diversity, as it is essential for our intended  
323 trial-based economic evaluation [14]. Previous randomized controlled trials researching the effects of  
324 PDAs for T2DM experienced recruitment challenges [8-11]. These trials reported difficulties in  
325 recruiting sufficient participants, timely recruitment, and inadvertent recruitment bias. Moreover, some  
326 trials were unable to include a representative sample of patients with T2DM [9, 11]. It is also important  
327 to acknowledge that the PDA has a digital format and questionnaires need to be completed digitally.  
328 This may pose a limitation for individuals with low digital literacy, especially among older adults [45-  
329 47]. We will therefore place a strong emphasis on the feasibility of the study processes in terms of  
330 recruitment, retention, and consent rates within the pilot study. This will improve our understanding of  
331 strategies to include a representative and diverse group of participants and we can apply these insights  
332 to the recruitment process of the intended trial-based economic evaluation.

333 HCPs in primary care practices are faced with a high workload, time constraints, and stress  
334 which are also identified as barriers to research participation [15, 16, 48]. To avoid willingness and  
335 capacity problems of the participating practices related to the study, it is important to limit time expenses  
336 and paperwork, and to provide adequate information and support. Therefore, as part of the pilot study,  
337 we focus on how we can support general practices in effectively managing the challenges associated  
338 with study participation. These insights will be instrumental in ensuring the successful implementation  
339 of the multistage program into routine practice while minimizing the additional burden on practices.



340           There are valid and reliable instruments available (except for the cost questionnaire) for the  
341 primary and secondary outcomes of the intended trial-based economic evaluation [32-35, 39, 40]. The  
342 measurement process can be complex since outcomes are collected using different methods, from  
343 different sources, and at various time points. It is important to avoid data management problems and  
344 ensure successful data triangulation in the large-scale study. Hence, the primary and secondary outcomes  
345 will be measured and analyzed during the small-scale pilot study. In the pilot study, we also focus on  
346 the understandability and accessibility of the measurement tools and possible improvements thereof.  
347 This is especially important since approximately 24.5% of the Dutch population experience low health  
348 literacy and may therefore face difficulties when completing questionnaires [49]. Overall, the insights  
349 gained from the pilot study will guide the refinement of the study procedures and intervention  
350 components for the intended trial-based economic evaluation.

351           Our pilot study will contribute to the existing knowledge of effectively implementing PDAs into  
352 clinical practice. Previous research showed that only 44% of existing PDAs for different conditions are  
353 effectively integrated into clinical practice following their trial [46]. The intended trial-based economic  
354 evaluation strengthens the limited evidence about the impact of person-centered care and SDM on mid  
355 and long-term outcomes such as treatment adherence, health outcomes, and societal costs. It will  
356 contribute to gaining a more comprehensive understanding of the potential benefits and challenges of  
357 integrating person-centered SDM interventions into practice. Addressing these knowledge gaps is  
358 essential to convince HCPs, policymakers, and payers to invest in the widespread implementation of  
359 effective SDM support for person-centered care.

360

## 361 **Dissemination plan**

362           The results of this pilot study will be disseminated by means of conference presentations and  
363 international peer-reviewed scientific journals. Moreover, attention will be given to promoting the  
364 multistage SDM program among patients with T2DM and healthcare professionals within primary care.  
365 This will help the future recruitment of patients with T2DM and primary care practices for the intended  
366 trial-based economic evaluation. Our collaboration with the steering group consisting of patients with

367 T2DM, healthcare professionals, and patient organizations, established at the beginning of the  
368 development of the multistage SDM program, will be continued for this pilot study. The steering group  
369 and our collaboration with care group ‘Huisarts & Zorg’ and PatientPlus add valuable expertise and  
370 experience from practice and policy as future end-users of our multistage SDM program. This  
371 collaboration will help improve the implementation and dissemination of the program.  
372

## 373 **References**

- 374 1. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: 2021. Available at:  
375 <https://www.diabetesatlas.org>.
- 376 2. American Diabetes Association Professional Practice C. 9. Pharmacologic Approaches to  
377 Glycemic Treatment: Standards of Care in Diabetes—2024. *Diabetes Care*.  
378 2023;47(Supplement\_1):S158-S78. doi: 10.2337/dc24-S009.
- 379 3. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of  
380 Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes  
381 Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes*  
382 *Care*. 2022;45(11):2753-86. doi: 10.2337/dci22-0034.
- 383 4. Nederlands Huisartsen Genootschap. NHG-standaard Diabetes mellitus type 2 (versie 5.6).  
384 2023.
- 385 5. Tichler A, Hertroijs D, Ruwaard D, Brouwers M, Elissen A. Development of a patient decision  
386 aid for type 2 diabetes mellitus: a patient-centered approach. *Research Square [Preprint]* [posted  
387 2023 Oct 10; cited 2023 Oct 11]. 2023. Epub 10 October 2023. doi:  
388 <https://doi.org/10.21203/rs.3.rs-3395717/v1>.
- 389 6. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people  
390 facing health treatment or screening decisions. *Cochrane Database Syst Rev*.  
391 2014;(1):CD001431. Epub 2014/01/28. doi: 10.1002/14651858.CD001431.pub4. PubMed  
392 PMID: 24470076.
- 393 7. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework  
394 for developing and evaluating complex interventions: update of Medical Research Council  
395 guidance. *BMJ*. 2021;374:n2061. doi: 10.1136/bmj.n2061.
- 396 8. Branda ME, LeBlanc A, Shah ND, Tiedje K, Ruud K, Van Houten H, et al. Shared decision  
397 making for patients with type 2 diabetes: a randomized trial in primary care. *BMC Health Serv*  
398 *Res*. 2013;13:301-. doi: 10.1186/1472-6963-13-301. PubMed PMID: 23927490.

- 399 9. Kellar I, Mann E, Kinmonth AL, Prevost AT, Sutton S, Marteau TM. Can informed choice  
400 invitations lead to inequities in intentions to make lifestyle changes among participants in a  
401 primary care diabetes screening programme? Evidence from a randomized trial. *Public Health*.  
402 2011;125(9):645-52. doi: <https://doi.org/10.1016/j.puhe.2011.05.010>.
- 403 10. Mathers N, Ng CJ, Campbell MJ, Colwell B, Brown I, Bradley A. Clinical effectiveness of a  
404 patient decision aid to improve decision quality and glycaemic control in people with diabetes  
405 making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice.  
406 *BMJ Open*. 2012;2(6):e001469. doi: [10.1136/bmjopen-2012-001469](https://doi.org/10.1136/bmjopen-2012-001469).
- 407 11. Mullan RJ, Montori VM, Shah ND, Christianson TJH, Bryant SC, Guyatt GH, et al. The  
408 Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. *Arch Intern Med*.  
409 2009;169(17):1560-8. doi: [10.1001/archinternmed.2009.293](https://doi.org/10.1001/archinternmed.2009.293).
- 410 12. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the  
411 what, why and how. *BMC Med Res Methodol*. 2010;10(1):1. doi: [10.1186/1471-2288-10-1](https://doi.org/10.1186/1471-2288-10-1).
- 412 13. Van Teijlingen E, Hundley V. The importance of pilot studies. *Social research update*.  
413 2001;(35):1-4.
- 414 14. Black SA. Diabetes, diversity, and disparity: what do we do with the evidence? *Am J Public*  
415 *Health*. 2002;92(4):543-8. doi: [10.2105/ajph.92.4.543](https://doi.org/10.2105/ajph.92.4.543). PubMed PMID: 11919048; PubMed  
416 Central PMCID: PMCPMC1447113.
- 417 15. McKinley N, McCain RS, Convie L, Clarke M, Dempster M, Campbell WJ, Kirk SJ. Resilience,  
418 burnout and coping mechanisms in UK doctors: a cross-sectional study. *BMJ Open*.  
419 2020;10(1):e031765. Epub 20200127. doi: [10.1136/bmjopen-2019-031765](https://doi.org/10.1136/bmjopen-2019-031765). PubMed PMID:  
420 31988223; PubMed Central PMCID: PMCPMC7045750.
- 421 16. West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and  
422 solutions. *J Intern Med*. 2018;283(6):516-29. Epub 20180324. doi: [10.1111/joim.12752](https://doi.org/10.1111/joim.12752).  
423 PubMed PMID: 29505159.
- 424 17. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT  
425 2010 statement: extension to randomised pilot and feasibility trials. *Pilot and Feasibility Studies*.  
426 2016;2(1):64. doi: [10.1186/s40814-016-0105-8](https://doi.org/10.1186/s40814-016-0105-8).

- 427 18. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT  
428 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med.*  
429 2013;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- 430 19. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013  
431 explanation and elaboration: guidance for protocols of clinical trials. *BMJ : British Medical*  
432 *Journal.* 2013;346:e7586. doi: 10.1136/bmj.e7586.
- 433 20. Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. *Pilot*  
434 *and Feasibility Studies.* 2019;5(1):37. doi: 10.1186/s40814-019-0423-8.
- 435 21. Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg  
436 (versie 2024). 2024. p. 38.
- 437 22. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al.  
438 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)  
439 Statement: Updated Reporting Guidance for Health Economic Evaluations. *Value Health.*  
440 2022;25(1):3-9. doi: <https://doi.org/10.1016/j.jval.2021.11.1351>.
- 441 23. InEen. Benchmark Transparante Ketenzorg 2022. Rapportage zorgprogramma's diabetes  
442 mellitus type 2, COPD, Astma en Vasculair Risico Management bij patiënten met een  
443 hartvaatziekte en een verhoogd risico op hartvaatziekten 2023.
- 444 24. Struijs JN, van Til JT, Baan CA. Experimenteren met de keten-dbc diabetes. Bilthoven: RIVM,  
445 2009.
- 446 25. Nederlands Huisartsen Genootschap (NHG). Behandeling bij diabetes type 2 2022. Available  
447 from: [https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-](https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-diabetes-type-2)  
448 [diabetes-type-2.](https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-diabetes-type-2)
- 449 26. Fayers PM, Jordhù MS, Kaasa S. Cluster-randomized trials. *Palliat Med.* 2002;16(1):69-70.  
450 doi: 10.1191/0269216302pm503xx.
- 451 27. Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization  
452 techniques for clinical trials. *J Athl Train.* 2008;43(2):215-21. Epub 2008/03/18. doi:  
453 10.4085/1062-6050-43.2.215. PubMed PMID: 18345348; PubMed Central PMCID:  
454 PMCPMC2267325.

- 455 28. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality  
456 criteria framework for patient decision aids: online international Delphi consensus process. *BMJ*  
457 (Clinical research ed). 2006;333(7565):417-. Epub 2006/08/14. doi:  
458 10.1136/bmj.38926.629329.AE. PubMed PMID: 16908462.
- 459 29. Elwyn G, O'Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, et al. Assessing the  
460 quality of decision support technologies using the International Patient Decision Aid Standards  
461 instrument (IPDASi). *PLoS One*. 2009;4(3):e4705. Epub 2009/03/05. doi:  
462 10.1371/journal.pone.0004705. PubMed PMID: 19259269; PubMed Central PMCID:  
463 PMCPMC2649534.
- 464 30. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot  
465 randomised trial to minimise the overall trial sample size for the external pilot and main trial for  
466 a continuous outcome variable. *Stat Methods Med Res*. 2016;25(3):1057-73. Epub 2015/06/21.  
467 doi: 10.1177/0962280215588241. PubMed PMID: 26092476; PubMed Central PMCID:  
468 PMCPMC4876429.
- 469 31. Yu CH, Ivers NM, Stacey D, Rezmovitz J, Telner D, Thorpe K, et al. Impact of an  
470 interprofessional shared decision-making and goal-setting decision aid for patients with diabetes  
471 on decisional conflict – study protocol for a randomized controlled trial. *Trials*. 2015;16(1):286.  
472 doi: 10.1186/s13063-015-0797-8.
- 473 32. O'Connor AM. Validation of a Decisional Conflict Scale. *Med Decis Making*. 1995;15(1):25-  
474 30. doi: 10.1177/0272989X9501500105.
- 475 33. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. The psychometric  
476 properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-  
477 making process. *J Med Internet Res*. 2014;16(1):e2-e. doi: 10.2196/jmir.3085. PubMed PMID:  
478 24389354.
- 479 34. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE:  
480 a fast and frugal patient-reported measure of shared decision making in clinical encounters.  
481 *Patient Educ Couns*. 2013;93(1):102-7. Epub 2013/06/19. doi: 10.1016/j.pec.2013.05.009.  
482 PubMed PMID: 23768763.

- 483 35. Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, Scholl I, van der Weijden T,  
484 Luyten GP, et al. Dutch Translation and Psychometric Testing of the 9-Item Shared Decision  
485 Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician  
486 Version (SDM-Q-Doc) in Primary and Secondary Care. PLoS One. 2015;10(7):e0132158. Epub  
487 2015/07/08. doi: 10.1371/journal.pone.0132158. PubMed PMID: 26151946; PubMed Central  
488 PMCID: PMC4494856.
- 489 36. Fox-Rushby J. CJ. Economic Evaluation. London: Oxford University Press; 2006.
- 490 37. [www.imta.nl](http://www.imta.nl) (iMTA Productivity and Health Research Group. Handleiding iMTA Medical Cost  
491 Questionnaire (iMCQ) Rotterdam: iMTA, Erasmus Universiteit Rotterdam, 2018)
- 492 38. [www.imta.nl](http://www.imta.nl) (iMTA Productivity and Health Research Group. Handleiding iMTA Productivity  
493 Cost Questionnaire (iPCQ). Rotterdam: iMTA, Erasmus Universiteit, 2018)
- 494 39. EuroQol. EuroQol 2017. Available from: [https://euroqol.org/eq-5d-instruments/eq-5d-3l-](https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/)  
495 [about/](https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/).
- 496 40. Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A  
497 measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol.  
498 2020;86(7):1281-8. Epub 20200518. doi: 10.1111/bcp.14193. PubMed PMID: 31823381;  
499 PubMed Central PMCID: PMC7319010.
- 500 41. Qualtrics. Provo, Utah, USA, 2005. Available from: <https://www.qualtrics.com/>.
- 501 42. Team R. RStudio: Integrated Development for R. 1.4.1106 ed. Boston, MA: RStudio, PBC;  
502 2020.
- 503 43. ATLAS.ti Scientific Software Development GmbH. ATLAS.ti Scientific Software  
504 Development GmbH.
- 505 44. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology.  
506 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa.
- 507 45. Hargittai E, Piper AM, Morris MR. From internet access to internet skills: digital inequality  
508 among older adults. Universal Access in the Information Society. 2019;18(4):881-90. doi:  
509 10.1007/s10209-018-0617-5.

- 510 46. Stacey D, Suwalska V, Boland L, Lewis KB, Pesseau J, Thomson R. Are Patient Decision Aids  
511 Used in Clinical Practice after Rigorous Evaluation? A Survey of Trial Authors. *Med Decis*  
512 *Making*. 2019;39(7):805-15. Epub 2019/08/20. doi: 10.1177/0272989x19868193. PubMed  
513 PMID: 31423911.
- 514 47. van Deursen AJ, van Dijk JA. The first-level digital divide shifts from inequalities in physical  
515 access to inequalities in material access. *New Media Soc*. 2019;21(2):354-75. Epub 2019/03/20.  
516 doi: 10.1177/1461444818797082. PubMed PMID: 30886536; PubMed Central PMCID:  
517 PMC6380454.
- 518 48. Brodaty H, Gibson LH, Waine ML, Shell AM, Lilian R, Pond CD. Research in general practice:  
519 a survey of incentives and disincentives for research participation. *Ment Health Fam Med*.  
520 2013;10(3):163-73. PubMed PMID: 24427184; PubMed Central PMCID: PMC3822664.
- 521 49. Willems AEM, Heijmans M, Brabers AEM, Rademakers J. Gezondheidsvaardigheden in  
522 Nederland: factsheet cijfers 2021. Utrecht: Nivel. 2022.

## 523 **Supporting information**

524 **S1 File. SPIRIT checklist.**

525 **S2 File. CONSORT checklist.**

526 **S3. File. Protocol**






Figure 1